Kaplan-Meier estimates of PFS and OS based on ctDNA detection at landmark time points during induction therapy. (A) PFS in patients with no detectable ctDNA (blue) compared with patients with detectable ctDNA (red) at the end of induction therapy. (B) OS in patients with no detectable ctDNA (blue) compared with patients with detectable ctDNA (red) at the end of induction therapy. (C) PFS in patients with no detectable ctDNA (blue) compared with patients with detectable ctDNA (red) after 2 cycles of induction therapy. (D) OS in patients with no detectable ctDNA (blue) compared with patients with detectable ctDNA (red) after 2 cycles of induction therapy. (E) PFS in patients with no detectable ctDNA (blue) compared with patients with detectable ctDNA (red) after 1 cycle of induction therapy. (F) OS in patients with no detectable ctDNA (blue) compared with patients with detectable ctDNA (red) after 1 cycle of induction therapy.